Amino-decorated mesoporous silica nanoparticles for controlled sofosbuvir delivery

Eur J Pharm Sci. 2020 Feb 15:143:105184. doi: 10.1016/j.ejps.2019.105184. Epub 2019 Dec 14.

Abstract

The present study describes synthesis of amino-decorated mesoporous silica nanoparticles (MSNs) for sustained delivery and enhanced bioavailability of sofosbuvir. Sofosbuvir is active against hepatitis C virus and pharmaceutically classified as class III drug according to biopharmaceutics classification system (BCS). MSNs were synthesized using modified sol-gel method and the surface was decorated with amino functionalization. Drug loaded MSNs were also grafted with polyvinyl alcohol in order to compare it with the amino-decorated MSNs for sustained drug release. The prepared MSNs were extensively characterized and the optimized formulation was toxicologically and pharmacokinetically evaluated. The functionalized MSNs of 196 nm size entrapped 29.13% sofosbuvir in the pores, which was also confirmed by the decrease in surface area, pore volume and pore size. The drug-loaded amino-decorated MSNs revealed an improved thermal stability as confirmed by thermal analysis. Amino-decorated MSNs exhibited Fickian diffusion controlled sofosbuvir release as compared with non-functionalized and PVA grafted MSNs. Amino-decorated MSNs were deemed safe to use in Sprague-Dawley rats after 14-days exposure as confirmed by the toxicological studies. More interestingly, we achieved a 2-fold higher bioavailability of sofosbuvir in Sprague-Dawley rats in comparison with sofosbuvir alone, and the Tmax was delayed 3-times indicating a sustained release of sofosbuvir.

Keywords: Functionalization; Mesoporous silica nanoparticles; Pharmacokinetics; Sofosbuvir; Surface area; Toxicology.

MeSH terms

  • Animals
  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / chemistry
  • Antiviral Agents* / pharmacokinetics
  • Antiviral Agents* / toxicity
  • Cell Survival / drug effects
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacokinetics
  • Delayed-Action Preparations / toxicity
  • Drug Carriers* / administration & dosage
  • Drug Carriers* / chemistry
  • Drug Carriers* / pharmacokinetics
  • Drug Carriers* / toxicity
  • Drug Liberation
  • Hep G2 Cells
  • Humans
  • Male
  • Nanoparticles* / administration & dosage
  • Nanoparticles* / chemistry
  • Nanoparticles* / toxicity
  • Polyvinyl Alcohol / chemistry
  • Porosity
  • Propylamines* / administration & dosage
  • Propylamines* / chemistry
  • Propylamines* / pharmacokinetics
  • Propylamines* / toxicity
  • Rats, Sprague-Dawley
  • Silanes* / administration & dosage
  • Silanes* / chemistry
  • Silanes* / pharmacokinetics
  • Silanes* / toxicity
  • Silicon Dioxide* / administration & dosage
  • Silicon Dioxide* / chemistry
  • Silicon Dioxide* / toxicity
  • Sofosbuvir* / administration & dosage
  • Sofosbuvir* / chemistry
  • Sofosbuvir* / pharmacokinetics
  • Sofosbuvir* / toxicity

Substances

  • Antiviral Agents
  • Delayed-Action Preparations
  • Drug Carriers
  • Propylamines
  • Silanes
  • Silicon Dioxide
  • Polyvinyl Alcohol
  • amino-propyl-triethoxysilane
  • Sofosbuvir